Dopamine receptor D2
Dopamine receptor D2
Dopamine Receptor D2 (DRD2)
Overview
Dopamine receptor D2 (DRD2), encoded by the DRD2 gene, is a member of the D2-like subfamily of G protein-coupled receptors (GPCRs) and represents one of the most pharmacologically significant dopaminergic targets in the central and peripheral nervous systems. Upon binding dopamine, DRD2 couples primarily to inhibitory Gi/o proteins, leading to suppression of adenylyl cyclase activity and downstream modulation of cAMP signaling, ion channel conductance, and gene expression. Its expression is widespread across the striatum, limbic system, hypothalamus, and pituitary gland, where it governs core physiological processes including motor control, reward processing, hormonal regulation, and cognition. The receptor exists in two functionally distinct isoforms — DRD2S (short) and DRD2L (long) — generated through alternative splicing, which differ in their G protein coupling efficiency and desensitization profiles.
Beyond its central roles in neurophysiology, DRD2 has long been established as a primary target in the pharmacotherapy of psychiatric and neurological disorders, including schizophrenia, Parkinson's disease, and hyperprolactinemia. In the pituitary, DRD2 is the predominant inhibitory regulator of prolactin secretion, and cabergoline (CAB), a high-affinity D2 agonist, is the first-line treatment for prolactinoma — a common pituitary adenoma characterized by excess prolactin production. Drug resistance to CAB-based therapies remains a clinical challenge, spurring mechanistic investigation into how DRD2 signaling is regulated at the molecular level. More broadly, the receptor's well-defined ligand-binding pocket and tractable three-dimensional structure have made it a benchmark target in computational drug discovery, particularly in the development and validation of AI-driven molecular design platforms.
Focus of Latest Publications
Recent publications highlight DRD2 as a subject of active investigation across two distinct research frontiers: mechanistic studies of receptor regulation in disease contexts, and computational drug design benchmarking.
In the domain of pituitary biology, a 2026 study published in the International Journal of Molecular Medicine (PMID: 41891968) investigated the molecular basis of resistance to cabergoline (CAB) in prolactinoma, focusing on the role of circular RNA OMA1 (circOMA1) delivered via exosomes. The study characterized DRD2 as a CAB-specific, high-affinity G protein-coupled receptor and demonstrated that circOMA1 promotes ubiquitination of DRD2 — a post-translational modification that targets the receptor for proteasomal degradation and thereby attenuates drug sensitivity. This finding provides a mechanistic explanation for acquired CAB resistance in prolactinoma patients and positions exosome-mediated circRNA transfer as a novel regulatory axis governing receptor abundance and drug responsiveness.
In parallel, DRD2 has emerged as a canonical benchmark target for evaluating AI-assisted molecular generation and optimization frameworks. A study published in the Journal of Molecular Modeling (PMID: 42118199) introduced a geometry-aware generative framework combining a GPS-VAE (Geometric Prior Structure Variational Autoencoder) with a Transformer-SELFIES architecture for structure-based de novo drug design. The authors validated this framework on DRD2 alongside Janus Kinase 2 (JAK2), demonstrating the system's capacity to generate chemically valid and geometrically plausible molecules tailored to the receptor's binding pocket. Separately, a study in the Journal of Chemical Information and Modeling (PMID: 42033344) benchmarked TRACE-GFN — a Transformer-integrated generative flow network (GFlowNet) designed for reaction-aware compound exploration guided by QSAR objectives — against DRD2, AKT serine/threonine kinase 1 (Akt1), and C-X-C motif chemokine receptor 4 (CXCR4), establishing DRD2 as part of a standard multi-target evaluation suite for generative molecular design. Additionally, research published in the European Journal of Medicinal Chemistry (PMID: 41785832) explored AI-driven discovery of protein-protein interaction (PPI) modulators targeting neuronal calcium sensor 1 (NCS-1), citing the well-characterized interaction between NCS-1 and DRD2 as a biologically relevant PPI axis of therapeutic interest.
Collectively, these studies underscore DRD2's dual significance: as a mechanistically complex therapeutic target whose intracellular regulation involves post-translational control and non-coding RNA networks, and as a structurally well-defined receptor serving as a gold-standard benchmark in the rapidly evolving field of generative AI drug discovery.
Key Publications
- Jun circOMA1 delivered by exosomes regulates DRD2‑mediated prolactinoma resistance. (International journal of molecular medicine, 2026, PMID 41891968): "This promoted ubiquitination of the CAB-specific, high-affinity G-protein-coupled receptor dopamine D2 receptor."
- May A geometry-aware generative framework integrating GPS-VAE and Transformer-SELFIES for structure-based de novo drug design. (Journal of molecular modeling, 2026, PMID 42118199): "We evaluated our proposed framework on Janus Kinase 2 (JAK2) and Dopamine D2 Receptor (DRD2) targets."
- May A Transformer for Reaction-Aware Compound Explorations with GFlowNet in QSAR-Guided Molecular Design. (Journal of chemical information and modeling, 2026, PMID 42033344): "In benchmark experiments involving dopamine receptor D2 (DRD2), AKT serine/threonine kinase 1 (AKT1), and C-X-C motif chemokine receptor 4 (CXCR4),"
- Apr An AI-based approach accelerates the discovery of protein-protein interaction modulators targeting NCS-1. (European journal of medicinal chemistry, 2026, PMID 41785832): "...the interaction between NCS-1 and the dopamine D2 receptor."